| Videos | September 6, 2017
Progression of Treatment in Colorectal Cancer Progression of Treatment in Colorectal Cancer
A 71-year-old Caucasian male presented with severe left lower quadrant painHe sought medical treatment after experiencing bloody diarrhea PMH: hypertension, managed with benazepril He is active and can perform daily activities without restrictions Laboratory findings: remarkable for CEA, 6.0 ng/mL Colonoscopy showed a mass in the descending colon which was biopsiedPathological findings: Moderately differentiated adenocarcinoma NGS mutation testing results wereNRAS, KRAS, HRAS, HER2, andBRAF wild-type CT of the chest, abdominal, and pelvis showed an 8-cm mass in the sigmoid colona 2-cm mass in the right lobe of the liver, and a 5-cm in the left lobe adjacent to the left hepatic vein Impression: metastatic disease, borderline resectable Treatment was initiated with FOLFIRI + bevacizumab Imaging at 3 and 6 months showed decreased size of the liver nodules, but was not resectable
July 2016
The patient complained of increased fatigue, requiring the need for frequent rest CT scan showed increasing size of the liver nodule (3 cm) and appearance of 3 new small liver lesions (<2 cm) He began therapy with FOLFOX + bevacizumab
February 2017
The patient reported weight loss, increasing fatigue, and shortness of breath CT scan revealed progressive disease with no improvement in the primary and metastatic lesion size and/or number A new pulmonary nodule was seen in the right lung He was switched to irinotecan + cetuximab PET/CT at 3 months showed stable disease At 6 months, he reported moderate improvement in fatigue Newsletter Stay up to date on practice-changing data in community practice.
Subscribe
October 1st, 2026 The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
October 1st, 2026 Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
October 1st, 2026 Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
September 30th, 2026 Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
September 30th, 2026 Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
September 30th, 2026 Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
September 30th, 2026 FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September 30th, 2026 September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.